FUSED AZABICYCLIC COMPOUNDS WHICH INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR

PROBLEM TO BE SOLVED: To provide the compounds and medicinal compositions useful in treating disorders induced or deteriorated by vanilloid receptor subtype 1 (VR1) activity. SOLUTION: There are provided the compounds represented by formula (I). The compounds are new VR1 antagonists which are useful...

Full description

Saved in:
Bibliographic Details
Main Authors WHITE TAMMIE K, DIDOMENICO STANLEY JR, GOMTSYAN ARTHUR R, BAYBURT EROL K, PERNER RICHARD J, LEE CHIH-HUNG, KOENIG JOHN R, DRIZIN IRENE, SCHMIDT ROBERT G, ZHENG GUO ZHU, TURNER SEAN C
Format Patent
LanguageEnglish
Published 10.02.2011
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide the compounds and medicinal compositions useful in treating disorders induced or deteriorated by vanilloid receptor subtype 1 (VR1) activity. SOLUTION: There are provided the compounds represented by formula (I). The compounds are new VR1 antagonists which are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and hyperactive bladder. COPYRIGHT: (C)2011,JPO&INPIT
Bibliography:Application Number: JP20100200674